Krystal Biotech
KRYS
275 hedge funds and large institutions have $3.8B invested in Krystal Biotech in 2025 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 101 increasing their positions, 97 reducing their positions, and 63 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 97
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.14% less ownership
Funds ownership: 95.83% → 95.68% (-0.14%)
8% less funds holding
Funds holding: 299 → 275 (-24)
11% less call options, than puts
Call options by funds: $60.6M | Put options by funds: $68M
24% less capital invested
Capital invested by funds: $4.98B → $3.8B (-$1.18B)
33% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$70.7M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$48M |
| 3 |
Goldman Sachs
New York
|
+$43.6M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.8M |
| 5 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$50.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$33.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$27.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$27M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$24.5M |
KRYS Hedge Fund Activity: Q2 2025 in Review
275 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2025, worth a combined $3.8B — down 24% from $4.98B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of KRYS and 42 opened new positions — a net loss of 21 holders — while 97 trimmed existing stakes and 101 added.
The largest buyer was Soleus Capital Management, adding an estimated $70.7M. The largest seller was UBS AM, cutting an estimated $50.1M.
- 275 institutional investors held Krystal Biotech (KRYS) as of Q2 2025, down from 299 in Q1 2025.
- Funds reported $3.8B of Krystal Biotech stock for Q2 2025, down 24% quarter-over-quarter.
- 42 funds opened new Krystal Biotech positions in Q2 2025 and 63 closed out, a net change of -21 holders.
- The largest Krystal Biotech buyer in Q2 2025 was Soleus Capital Management, an estimated $70.7M added.
- The largest Krystal Biotech seller in Q2 2025 was UBS AM, an estimated $50.1M sold.
Based on aggregated 13F filings for Q2 2025.